Pfizer (PFE) Income from Discontinued Operations (2010 - 2014)
Pfizer (PFE) posted quarterly Income from Discontinued Operations of 6000000.0 for Q4 2014, up 66.67% year-over-year from 3600000.0 in Q4 2013, and down 100.0% quarter-over-quarter from 3000000.0 in Q3 2014.
Pfizer (PFE) Income from Discontinued Operations (2010 - 2014) Analysis & Trends
Pfizer (PFE) has reported Income from Discontinued Operations for 5 consecutive years, with 6000000.0 the latest figure, recorded in Q4 2014.
- In Q4 2014, Income from Discontinued Operations rose 66.67% year-over-year to 6000000.0; the TTM figure through Dec 2014 stood at 29000000.0 (down 113.24% YoY), while the FY2019 annual figure was 4000000.0, down 60.0% from the prior year.
- Income from Discontinued Operations slipped to 6000000.0 in Q4 2014 per PFE's latest filing, from 3000000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 582000000.0 in Q4 2011 and bottomed at 95000000.0 in Q4 2010.
- Historically, Income from Discontinued Operations has averaged 81882352.94 across 5 years, with a median of 30000000.0 in 2011.
- Annual changes were most pronounced in 2012 — Income from Discontinued Operations jumped 766.67% — and 2013, when it tumbled 130.0%.
- Pfizer's Income from Discontinued Operations stood at 95000000.0 in 2010, then surged by 712.63% to 582000000.0 in 2011, then sank by 89.69% to 60000000.0 in 2012, then slumped by 130.0% to 18000000.0 in 2013, then soared by 66.67% to 6000000.0 in 2014.
- Business Quant data shows PFE's Income from Discontinued Operations at 6000000.0 in Q4 2014, 3000000.0 in Q3 2014, and 2000000.0 in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 8.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | -6.00 Mn |
| Sep 28, 2014 | -3.00 Mn |
| Jun 29, 2014 | -2.00 Mn |
| Dec 31, 2013 | -18.00 Mn |
| Sep 29, 2013 | 36.00 Mn |
| Jun 30, 2013 | 141.00 Mn |
| Dec 31, 2012 | 60.00 Mn |
| Sep 30, 2012 | 225.00 Mn |
| Jul 1, 2012 | 260.00 Mn |
| Dec 31, 2011 | 582.00 Mn |
| Oct 2, 2011 | 96.00 Mn |
| Jul 3, 2011 | 30.00 Mn |
| Apr 3, 2011 | 10.00 Mn |
| Dec 31, 2010 | -95.00 Mn |
| Oct 3, 2010 | 26.00 Mn |
| Jul 4, 2010 | 31.00 Mn |
| Apr 4, 2010 | 19.00 Mn |